Interní Med. 2010; 12(1): 26-32

Breast cancer - the major problem also in the 21. century

MUDr.Jana Prausová, Ph.D., MBA
Radioterapeuticko-onkologické oddělení FN v Motole a 2. LF UK v Praze

The paper summarised current knowledge from epidemiology and aetiology of breast cancer, emphasized risk factors of sporadic and

hereditary cancer. Different types of histology and imunohistological classification are described. Baseline diagnostic procedures for

staging of the disease are reviewed. Treatment strategy based on different risk factors reflecting the stage of the disease, prognostic

and predictive factor is featured. The importance of the prevention is highlighted for early detection of breast cancer.

Keywords: breast cancer, prognostic and predictive factors, treatment strategy, prevention

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prausová J. Breast cancer - the major problem also in the 21. century. Interní Med. 2010;12(1):26-32.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Mužík J, Kubásek M, et al. Český národní webový portál: Epidemiologie nádorů (online). Masarykova Univerzita 2005 (cit. 2007 - 08 - 03). (Dostupný www: http://www.svod.cz).
    2. Daly M. NCCN Practise guidelines: Genetics/Familiar High - risk cancer screening. Oncology. Huntington 1999; 13: 161-183.
    3. Ford D, Easton DF, Stratton M, et al. Genetic heterogenity and penetrance analysis of the BRCA-1 and BRCA-2 genes in breast cancer families. Am J Hum Genet. 1998; 62: 676-689. Go to original source... Go to PubMed...
    4. Kauf ND, Perez-Segura P, Robson ME, et al. Incidence of non-founder BRCA-1 and BRCA-2 mutations in high-risk Ashkenazi breast and ovarian cancer families. J Med Genet. 2002; 39: 611-614. Go to original source... Go to PubMed...
    5. Prausová J, Kubáčková K, Hoch J. Několik poznámek k molekulární genetice kolorektálního karcinomu. Klinická onkologie 2000; 13 (5): 151-154.
    6. Klener P. Klinická onkologie. Praha: Galén 2002: 495-497.
    7. Koukoulis GN. Hormone replacement therapy and breast cancer risk. Ann NY Acat sci 2000; 900: 422-428. Go to original source... Go to PubMed...
    8. Pazdur R, Coia LR, Hoskins WJ, Wagman LD. Cancer Management: A Multidisciplinary Approach. The Oncology Group a Division of SCP communications. INC. Oncology News International. 2003. 163-168.
    9. Abrahámová J, Dušek L, a kol. Možnosti včasného záchytu rakoviny prsu. Praha: Grada Publishing Avicenum 2003: 41-60.
    10. Abrahámová J, Povýšil C, Horák J, et al. Atlas nádorů prsu. Praha: Grada Publishing 2000: 225-264 s.
    11. Mrhalová M, Kubáčková K, Prausová J, Kodet R. ERBB2 u nemocných s karcinomy mléčné žlázy - přínos a úskalí po 6 letech laboratorních zkušeností. VI. Motolské dny. Sborník abstrakt. Praha 2004.
    12. Kodet R, Prausová J. Klasifikace nádorů. In: Koutecký a spol. Klinická onkologie I. Riopress 2004: 151-157.
    13. Eisen A, Weber BL. Prophylactic mastectomy for BRCA1 and BRCA-2 mutation - Facts and controversy. New Engl J Med 2001; 345: 207-209. Go to original source... Go to PubMed...
    14. Ewans AJ, Wilson ARM, Blamey RW, et al. Atlas of breast disease management. London 1998. W. B. Saunders.
    15. Prausová J. Karcinom prsu. In: Klinická onkologie II. Koutecký I a kol. (v tisku).
    16. Linke Z, Kubáčková K, Prausová J. Docetaxel v léčbě karcinomu prsu. Klinická onkologie 2000; 13, 1: 22-26.
    17. Prausová J. Hormonální terapie. In: Klinická onkologie Koutecký I a kol. Riopress 2004: 192-194.
    18. Klener P. Klinická onkologie. Praha: Galén 2002: 47 s.
    19. Prausová J, Kubáčková K. Cílená molekulární léčba - onkologická terapie pro 21. století. VI. Motolské dny. Sborník abstrakt. Praha 2004.
    20. Průša R, Kukačka J, Prausová J, Pechová M. Audit of serum HER-2/neu, CA 15-3 and CEA levels in 115 breast cancer patients. XIX. International Congress of Clinical Chemistry. Washington DC 2006. Abstract 05-A-314-AACC.
    21. Stankušová H, Kodet R, Kubáčková K, et al. Zvýšená exprese onkogenu HER-2 u nemocných s karcinomem prsu a její korelace s průběhem onemocnění. Brněnské onkologické dny 2003. Sborník abstrakt.
    22. De Vita VT jr, Hellman S, Rosenberg SA. Cancer Principles & Practice of Oncology - 7th Edition. Lippincott Williams &Wilkins 2005: 129-137.
    23. Wald M. Lymfedém - komplikace komplexní léčby karcinomu prsu. Onkologie 2009, 1: 32-35.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.